BridgeMD
Real-world study to evaluate how effective and safe Pegcetacoplan is in patients with rare kidney diseases called C3G or IC-MPGN in multiple countries (PRISMC3)
EU CTIS ID: 2025-524487-37-00
What this study is testing
To describe the real-world clinical effectiveness of pegcetacoplan in participants with C3G or primary IC-MPGN.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have received or plan to receive pegcetacoplan for the treatment of C3G or primary IC-MPGN.
- Provided signed and dated informed consent. For participants under the legal age signed and dated informed consent is provided by the participant’s legally authorised representative. Assent will also be obtained from paediatric participants as required by local regulations.
You likely can't join if
- Receiving an investigational treatment for C3G or primary IC-MPGN at the time of pegcetacoplan initiation.
- Initiated treatment with pegcetacoplan in an interventional study.
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- United Kingdom
- Australia
- Korea, Republic of
- Taiwan
- Switzerland
- Saudi Arabia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; United Kingdom; Australia; Korea, Republic of; Taiwan; Switzerland and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.